Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'.
Ganesh RaghuMarya GhazipuraThomas R FlemingKerri I AronsonJürgen BehrKevin K BrownKevin R FlahertyElla A KazerooniToby M MaherLuca RicheldiJoseph A LaskyJeffrey J SwigrisRobert BuschLili GarrardDong-Hyun AhnJi LiKhalid PuthawalaGabriela RodalSally SeymourNargues WeirSonye K DanoffNeil EttingerJonathan GoldinMarilyn K GlassbergLeticia Kawano-DouradoNasreen KhalilLisa LancasterDavid A LynchYolanda MagetoImre NothJessica E ShoreMarlies WijsenbeekRobert BrownDaniel GroganDorothy IveyPatrycja GolinskaBanu A Karimi-ShahFernando J MartinezPublished in: American journal of respiratory and critical care medicine (2024)
This report, detailing the proceedings of this pivotal symposium, suggests a potential turning point in designing future IPF clinical trials more attuned to outcomes meaningful to patients, and documents the collective agreement across multidisciplinary stakeholders on the importance of anchoring IPF trial endpoints on real patient experiences-namely, how they feel, function, and survive. There is considerable optimism that clinical care in IPF will progress through trials focused on patient-centric insights, ultimately guiding transformative treatment strategies to enhance patients' quality of life and survival.
Keyphrases